Warning letter enforcement begins in September
The FDA has announced a new programme regarding the issuance of warning letters to the pharmaceutical industry.
The FDA has announced a new
FDA 483 forms are issued to companies after an inspection to highlight “objectionable conditions” relating to the manufacturing process or products, according to the announcement. Companies are asked to respond to the FDA if they have an objection to an observation or if they have a corrective action plan for the observations noted. Warning letters, on the other hand, are issued when the agency, after a thorough review, finds a significant violation of the Federal Food, Drug, and Cosmetic Act during an inspection.
Because a company’s response or in most cases, multiple responses to an FDA 483 form can delay the issuance of a warning letter, the agency is now planning to issue a warning letter when appropriate if the company fails to respond to a 483 within 15 business days. If a response to a 483 is received within 15 business days, the FDA will conduct a review of the response “before determining whether to issue a warning letter.”
If a warning letter is still issued after receiving a firm’s timely response to 483 observations, the warning letter will recognize that response. If 483 observation responses are received after the 15-day period, and the agency issues a warning letter, the FDA will consider those responses to be direct responses to the warning letter rather than to the 483.
The FDA reiterates in the announcement that the agency can issue a warning letter at any time, independent of receiving a 483 response.
The programme, which correlates directly with FDA Commissioner Hamburg’s
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
